Hernday Natasha — SEC Form 4 filings
SEC reporting owner CIK 1780547. 9 Form 4 filings on record with FilingPulse; latest filed 2026-07-14.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-05-17 to 2026-07-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| XOMA Royalty Corp (XOMA) | Director | 4 | — | — | 11 |
| Janux Therapeutics, Inc. (JANX) | Director | 4 | — | — | 10 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) | Director | 1 | — | — | 5 |
Form 4 filings — Hernday Natasha
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-14 | 4 | XOMA Royalty Corp (XOMA) | Other (J): 9,304 · Disposition to issuer (D): 4,000 · Disposition to issuer (D): 13,251 (derivative) @ $0 · Disposition to issuer (D): 5,101 (derivative) @ $0 · Disposition to issuer (D): 8,996 (derivative) @ $0 · Disposition to issuer (D): 10,967 (derivative) @ $0 · +1 more | EDGAR |
| 2026-06-12 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | XOMA Royalty Corp (XOMA) | Grant/award (A): 3,586 @ $0 | EDGAR |
| 2025-06-13 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | XOMA Royalty Corp (XOMA) | Grant/award (A): 5,971 @ $0 | EDGAR |
| 2024-07-24 | 4/A | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 1,231 @ $0 · Grant/award (A): 4,111 (derivative) @ $0 | EDGAR |
| 2024-07-22 | 4 | Janux Therapeutics, Inc. (JANX) | Grant/award (A): 5,000 @ $0 · Grant/award (A): 2,500 @ $0 · Grant/award (A): 16,700 (derivative) @ $0 · Grant/award (A): 8,350 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) | Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 7,650 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 17,500 (derivative) | EDGAR |
| 2024-05-17 | 4 | XOMA Corp (XOMA) | Grant/award (A): 3,035 @ $0 · Grant/award (A): 4,881 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1780547 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →